Filtered By:
Source: Clinical Cardiology
Condition: Bleeding

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 38 results found since Jan 2013.

Where There's Smoke, There's Fire? Significance of Atrial Fibrillation in Young Patients
ConclusionsAtrial fibrillation occurs in young patients with and without structural heart disease. Young AF patients without comorbidities rarely develop CVD during the first years after diagnosis. Yet, an SVT is found in a high proportion of young AF patients; AF may be first manifestation of SVT. Therefore, young patients should undergo further evaluation for SVT
Source: Clinical Cardiology - February 5, 2016 Category: Cardiology Authors: Alexander Wutzler, Sophie von Ulmenstein, Philipp Attanasio, Martin Huemer, Abdul Shokor Parwani, Katharina Völk, Florian Blaschke, Leif‐Hendrik Boldt, Wilhelm Haverkamp Tags: Clinical Investigations Source Type: research

Direct oral anticoagulant use in nonvalvular atrial fibrillation with valvular heart disease: a systematic review
In conclusion, subanalyses of DOAC landmark AF trials revealed that dabigatran, rivaroxaban, and apixaban may be safely used in AF patients with certain types of VHD: aortic stenosis, aortic regurgitation, and mitral regurgitation. More evidence is needed before routinely recommending these agents for patients with bioprosthetic valves or mild mitral stenosis. Patients with moderate to severe mitral stenosis or mechanical valves should continue to receive warfarin, as these patients were excluded from all landmark AF trials.
Source: Clinical Cardiology - December 21, 2016 Category: Cardiology Authors: Ryan E. Owens, Rajesh Kabra, Carrie S. Oliphant Tags: Reviews Source Type: research

Intracardiac echocardiography for verification for left atrial appendage thrombus presence detected by transesophageal echocardiography: the ActionICE II study
ConclusionsWith TEE, a false positive of an LAA thrombus may be indicated, especially when a thrombus is described as soft rather than solid. Our study suggests that ICE may be a valuable option for verification of a TEE‐based diagnosis of a thrombus.
Source: Clinical Cardiology - February 12, 2017 Category: Cardiology Authors: Jakub Baran, Beata Zaborska, Roman Piotrowski, Malgorzata Sikora ‐Frąc, Ewa Pilichowska‐Paszkiet, Piotr Kułakowski Tags: CLINICAL INVESTIGATIONS Source Type: research

Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation
ConclusionsManagement of anticoagulation among AF patients undergoing CIED implantation is highly variable, with OAC being interrupted in more than half of both warfarin‐ and NOAC‐treated patients. Bleeding and stroke events were infrequent in both warfarin and NOAC‐treated patients.
Source: Clinical Cardiology - May 1, 2017 Category: Cardiology Authors: Eric Black ‐Maier, Sunghee Kim, Benjamin A. Steinberg, Gregg C. Fonarow, James V. Freeman, Peter R. Kowey, Jack Ansell, Bernard J. Gersh, Kenneth W. Mahaffey, Gerald Naccarelli, Elaine M. Hylek, Alan S. Go, Eric D. Peterson, Jonathan P. Piccini, Tags: CLINICAL INVESTIGATIONS Source Type: research

Real ‐world incidence of efficacy and safety outcomes in patients on direct oral anticoagulants with left ventricular systolic dysfunction at a tertiary referral center
ConclusionsOur findings are largely compatible with the results of LVSD or HF subgroups in RE‐LY, ROCKET‐AF, and ARISTOTLE trials and add to increasing confidence that DOACs can be safely used for stroke and systemic embolism prevention in patients with LVSD.
Source: Clinical Cardiology - November 1, 2017 Category: Cardiology Authors: Andrew S. Tseng, J. William Schleifer, Win ‐Kuang Shen, Robert McBane, Sunil Mankad, Heidi Esser, Darko Vucicevic, Fadi E. Shamoun Tags: CLINICAL INVESTIGATIONS Source Type: research

Incidence of thromboembolic and bleeding events in patients with newly diagnosed nonvalvular atrial fibrillation: An Asian multicenter retrospective cohort study in Singapore
ConclusionsSAPT and DAPT are less effective than warfarin in NVAF patients. DOACs may be considered in view of lower risk of overall bleed.
Source: Clinical Cardiology - November 1, 2017 Category: Cardiology Authors: Xue Ting Wee, Lih Maan Ho, Han Kiat Ho, Joyce Yu ‐Chia Lee, Chun Wei Yap, Henry William, Linus Chong En Chan, Hooi Ching Tay, Cynthia Eei Mei Goh, Doreen Su‐Yin Tan Tags: CLINICAL INVESTIGATIONS Source Type: research

Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting
Patients with atrial fibrillation affected by an acute coronary syndrome have indications for oral anticoagulation and dual antiplatelet therapy with aspirin and a P2Y12 adenosine diphosphate receptor inhibitor after coronary artery stenting. The concurrent use of all 3 agents, termed triple oral antithrombotic therapy, significantly increases the risk of bleeding. To date, there is a lack of evidence on the proper combination and duration of anticoagulant and antiplatelet agents in patients with indications for both therapies. As such, care has been guided by expert opinion, and there is wide variation in clinician practi...
Source: Clinical Cardiology - July 1, 2013 Category: Cardiology Authors: Grant W. Reed, Christopher P. Cannon Tags: Review Source Type: research

Postdischarge International Normalized Ratio Testing and Long‐term Clinical Outcomes of Patients With Heart Failure Receiving Warfarin: Findings From the ADHERE Registry Linked to Medicare Claims
ConclusionsPostdischarge outpatient INR testing in patients with heart failure complicated by atrial fibrillation or valvular heart disease was high. INR testing was associated with improved survival and fewer myocardial infarctions at 1 year but was not independently associated with other adverse clinical events.
Source: Clinical Cardiology - October 1, 2013 Category: Cardiology Authors: Laura G. Qualls, Melissa A. Greiner, Zubin J. Eapen, Gregg C. Fonarow, Roger M. Mills, Winslow Klaskala, Adrian F. Hernandez, Lesley H. Curtis Tags: Clinical Investigation Source Type: research

Practical Considerations for Using Novel Oral Anticoagulants in Patients With Atrial Fibrillation
Abstract Novel oral anticoagulants, including dabigatran, rivaroxaban, and apixaban, represent new options for preventing stroke in patients with atrial fibrillation, as shown by the results from large, randomized phase III trials. Because of their greater specificity, rapid onset of action, and predictable pharmacokinetics, the novel oral anticoagulants (dabigatran, rivaroxaban, and apixaban) address several limitations of warfarin or other vitamin K antagonists in day‐to‐day clinical practice. However, a range of practical questions relating to the novel oral anticoagulants has emerged, including topics such as patie...
Source: Clinical Cardiology - November 19, 2013 Category: Cardiology Authors: Irene Savelieva, A. John Camm Tags: Review Source Type: research

One‐Year Outcome of Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting: An Analysis of the AFCAS Registry
ConclusionsIn this large, real‐world population of AF patients undergoing PCI‐S, TT was the antithrombotic regimen most frequently prescribed. Although several limitations need to be acknowledged, in our study the 1‐year efficacy and safety of TT, dual antiplatelet therapy, and VKA plus clopidogrel was comparable.
Source: Clinical Cardiology - January 30, 2014 Category: Cardiology Authors: Andrea Rubboli, Axel Schlitt, Tuomas Kiviniemi, Fausto Biancari, Pasi P. Karjalainen, Josè Valencia, Mika Laine, Paulus Kirchhof, Matti Niemelä, Saila Vikman, Gregory Y. H. Lip, K. E. Juhani Airaksinen, Tags: Clinical Investigations Source Type: research

Comparison of Clinical Trial Outcome Patterns in Patients Following Acute Coronary Syndromes and in Patients With Chronic Stable Atherosclerosis
ConclusionsPatients with ACS enrolled while in the hospital appear to have different risk profiles for ischemic and bleeding outcomes compared with outpatients enrolled with CSA, including those patients with ACS after the acute phase.
Source: Clinical Cardiology - February 1, 2014 Category: Cardiology Authors: Kenneth W. Mahaffey, Daniel M. Wojdyla, Karen S. Pieper, Pierluigi Tricoci, John H. Alexander, A. Michael Lincoff, Danielle M. Brennan, Deepak L. Bhatt, Lars Wallentin, Robert A. Harrington Tags: Clinical Investigation Source Type: research

Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban
ConclusionsIn this large observational study, the MB rate was generally consistent with the registration trial results, and fatal bleeds were rare.
Source: Clinical Cardiology - December 1, 2014 Category: Cardiology Authors: Sally Tamayo, W. Frank Peacock, Manesh Patel, Nicholas Sicignano, Kathleen P. Hopf, Larry E. Fields, Troy Sarich, Shujian Wu, Daniel Yannicelli, Zhong Yuan Tags: Quality and Outcomes Source Type: research

The HAS‐BLED Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta‐analysis
ABSTRACT Our objective was to compare the diagnostic accuracy between the HAS‐BLED score and any of HEMORR2HAGES, ATRIA, CHADS2, or CHA2DS2‐VASc scores in anticoagulated patients with atrial fibrillation. We systematically searched the Cochrane Library, MEDLINE, PubMed, and Embase databases for relevant studies. Data were extracted and analyzed according to predefined clinical endpoints. Eleven studies were identified. Discrimination analysis demonstrates that HAS‐BLED has no significant C‐statistic differences for bleeding risk prediction compared with ATRIA or HEMORR2HAGES, but it has significant differences comp...
Source: Clinical Cardiology - September 29, 2015 Category: Cardiology Authors: Wengen Zhu, Wenfeng He, Linjuan Guo, Xixing Wang, Kui Hong Tags: Review Source Type: research

Initial Experience With Novel Oral Anticoagulants During the First 45 Days After Left Atrial Appendage Closure With the Watchman Device
ConclusionsOur pilot study suggests that NOAC therapy within the first 45 days after interventional LAA closure is safe and effective.
Source: Clinical Cardiology - September 1, 2015 Category: Cardiology Authors: Leif I. Bösche, Faegheh Afshari, Dominik Schöne, Aydan Ewers, Andreas Mügge, Michael Gotzmann Tags: Clinical Investigations Source Type: research

Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications
ConclusionsThe risk of bleeding and ischemic complications among patients on TT is similar between those on ticagrelor and clopidogrel. However, caution with use of bridging anticoagulation should be taken when using ticagrelor.
Source: Clinical Cardiology - January 8, 2016 Category: Cardiology Authors: Angel Fu, Kuljit Singh, Joseph Abunassar, Nikita Malhotra, Michel Le May, Marino Labinaz, Christopher Glover, Jean‐Francois Marquis, Michael Froeschl, Alexander Dick, Benjamin Hibbert, Aun‐Yeong Chong, Derek Y. F. So, Tags: Clinical Investigations Source Type: research